On December 26, AstraZeneca China WeChat official account announced that AstraZeneca had signed a final agreement on the acquisition proposal of Genxi Biology. This proposed acquisition will add GC012FCAR-T cell therapy to AstraZeneca's cell therapy pipeline. GC012F, built on the FasTCAR technology platform, is an innovative BCMA/CD19 dual target autologous chimeric antigen receptor T cell therapy (CAR-T) in the clinical stage, which is expected to become a next-generation treatment plan for multiple myeloma, other types of malignant hematological tumors, and autoimmune diseases (including systemic lupus erythematosus (SLE)).
AstraZeneca mentioned that the value of this transaction is approximately $1.2 billion. Genxi Biotechnology will continue to operate as a wholly-owned subsidiary of AstraZeneca in China and the United States.